Biovista is pleased to announce the signature of a grant agreement within the remit of the EU’s Innovative Medicines Initiative (IMI). Starting in March 2019, the 3.5 year “NeuroDeRisk” project aims to advance the industry’s ability to tackle three of the most challenging adverse effects: seizures, psychological/psychiatric changes, and peripheral neuropathies. Together with EFPIA members … Read More
Biovista is pleased to announce that its patent application for the use of tetracyclic pyrazinoindoles has issued in the EU. This new patent (European patent No.: 2375900) has title “METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRZINOINDOLES” was issued on March 2, 2016.
Current therapeutic strategies for myalgic encephalomyelitis/chronic fatigue syndrome: results of an online survey A new paper co-authored by Biovista and the Solve ME/CFS Initiative has just been published. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, poorly understood disorder that causes only a small number of the approximately 2.5 million Americans to receive proper diagnosis. … Read More
Charlottesville, June 10, 2014 Biovista announces online environment for in-context selling of life science products Biovista announced today the availability of its viz.it solution. Aimed at reagent and life-sciences product companies viz.it integrates seamlessly with customer web sites and their online product catalogs and payment systems. Short for “visualize it”, viz.it lets scientists/researchers browse through … Read More
Biovista Inc., Charlottesville, July 7, 2010: Biovista today announced that it is a featured company in InsightPharma’s report on Drug Repositioning. The report “Drug Repositioning: Extracting Added Value from Prior R&D Investments” by Dr. Hermann A.M. Mucke explains the basic issues surrounding drug repositioning as a pipeline development and/or lice cycle management strategy, covers the … Read More